BioCardia's Positive Consultation with Japan PMDA
BioCardia, Inc. is making strides in the therapeutic landscape for cardiovascular conditions. This prominent company has recently achieved a significant milestone by concluding a productive consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA). This meeting revolved around the future of BioCardia’s lead therapeutic product, BCDA-01, which is aimed at addressing ischemic heart failure characterized by reduced ejection fraction (HFrEF).
Key Outcomes from the Consultation
Peter Altman, Ph.D., who serves as BioCardia’s President and Chief Executive Officer, shared insights into the outcomes of the consultation. Among the pivotal points is the invitation from PMDA for another consultation following the final clinical data submission, with a special emphasis on assessing the evidence supporting safety and efficacy claims for the BCDA-01 program. Further, PMDA has shown a willingness to consider results from the CardiAMP Heart Failure Trial as appropriate evidence for registering the CardiAMP Cell Therapy System for heart failure patients in Japan.
Future Expectations for BCDA-01
As BioCardia moves forward, they are focused on finalizing data from the thoroughly enrolled CardiAMP Heart Failure Trial, which comprises 125 patients. The company expects that the final data will be available early in the coming year, and this will certainly be a critical step in the journey of BCDA-01.
Advancements in Cardiac Treatments
The CardiAMP Cell Therapy is at the forefront of innovative approaches for treating HFrEF. It has already received Breakthrough Designation from the FDA, specifically from the Center for Biological Evaluation and Research (CBER). The ongoing development of this promising therapy is also bolstered by support from the Maryland Stem Cell Research Fund, giving it a solid foundation for success.
Support and Funding for Clinical Trials
Moreover, BioCardia’s clinical trials in the United States, including both BCDA-01 and BCDA-02, benefit from reimbursement from the Centers for Medicare and Medicaid Services (CMS). This financial backing plays an essential role in ensuring that research into these revolutionary therapies progresses unimpeded.
About BioCardia and Its Innovative Technologies
BioCardia, based in Sunnyvale, California, is recognized as a global pioneer in cellular and cell-derived therapies tailored for cardiovascular and pulmonary diseases. The company’s innovative platforms, including CardiAMP autologous and CardiALLO allogeneic cell therapies, highlight their commitment to advancing treatment options. These technologies are paired with BioCardia’s Helix biotherapeutic delivery and Morph vascular navigation product platforms, creating a comprehensive approach to therapy administration.
Contact Information for Inquiries
For reach-outs regarding investor relations, Miranda Peto leads investor communications at BioCardia. She can be contacted via email at mpeto@BioCardia.com or by phone at 650-226-0120. Additionally, David McClung, the Chief Financial Officer, is available for investor inquiries via investors@BioCardia.com, also at the same phone number. This accessibility highlights the company's commitment to transparency and communication with stakeholders.
Frequently Asked Questions
What is BCDA-01?
BCDA-01 is BioCardia’s primary therapeutic asset aiming to treat ischemic heart failure with reduced ejection fraction.
What did BioCardia discuss with the PMDA?
The discussion involved the next steps for submitting registration for BCDA-01 and the potential for future consultations on clinical data.
What is the significance of the Breakthrough Designation?
The Breakthrough Designation by the FDA allows expedited development and review processes for therapies that show substantial improvement over existing options.
When can we expect data from the CardiAMP Heart Failure Trial?
The final data from the trial involving 125 patients is anticipated to be available early in the coming year.
How does BioCardia support its clinical trials financially?
BioCardia’s clinical trials are supported by reimbursement from the Centers for Medicare and Medicaid Services (CMS), facilitating ongoing research.
